Search Videos and More
News
Treatment Decisions in New Era of Individualized Therapy For Metastatic Hormone-Sensitive Prostate Cancer Guided by Dana-Farber Case Study
Oncologists have traditionally prescribed androgen deprivation therapy (ADT) alone for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
News
Study Sends Strong Signal Not to Sequence Immune Checkpoint Inhibitors in Advanced Kidney Cancer
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: primary PFS analysis from the Phase 3, randomized, open-label CONTACT-03 study
Symposium
2023 ASCO GU Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the clinical updates you need to know from ASCO GU 2023.
News
Dana-Farber Researchers Launch New Project to Investigate How Neighborhoods Contribute to Prostate Cancer Inequity
Researchers at Dana-Farber Cancer Institute and the Rutgers University Cancer Institute are investigating what it is about neighborhoods that may increase a Black man’s risk of dying from prostate cancer.
News
Newly Identified Regulator in Prostate Cancer Cells Could Serve as Drug Target for Advanced Tumors
Aiming to discover new targets for blocking androgen receptor activity, a Dana-Farber-led team has identified a critical regulator of AR signaling that prostate cancer cells depend on, according to their publication in Cell Reports.
Video
2022 GU ASCO Bladder Cancer Highlights
Bladder Cancer Highlights featuring Guru Sonpavde, MD
Video
2022 GU ASCO Prostate Cancer Highlights
Prostate Cancer Highlights featuring Jacob Berchuck, MD and Chris Sweeney, MBBS
Video
2022 GU ASCO Kidney Cancer Highlights
Kidney Cancer Highlights featuring Vincent Xu, MD and Toni Choueiri, MD
Symposium
2022 ASCO GU Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review highlights from the 2022 ASCO GU Symposium.
News
Dana-Farber Research Supports FDA Approval of Immunotherapy Drug Given After Surgery for Certain Patients with Kidney Cancer
Pembrolizumab is the first drug approved as adjuvant therapy for patients with kidney cancer considered at high risk of relapse.
Video
Rare Cancer: A Father's Journey with Medullary Kidney Cancer
A father and Air Force recruiter details his journey at Dana-Farber Cancer Institute with medullary kidney cancer - a rare cancer disproportionately affecting African Americans.
News
Targeted Drug Shows Activity Against Brain Metastases in Kidney Cancer
A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.